Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OLSALAZINE IS CONTRAINDICATED DURING PELVIC RADIATION-THERAPY - RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL-TRIAL
Autore:
MARTENSON JA; HYLAND G; MOERTEL CG; MAILLIARD JA; OFALLON JR; COLLINS RT; MORTON RF; TEWFIK HH; MOORE RL; FRANK AR; URIAS RE; DEMING RL;
Indirizzi:
MAYO CLIN & MAYO FDN,200 1ST ST SW ROCHESTER MN 55905 QUAIN & RAMSTAD CLIN BISMARCK ND 00000 UNIV NEBRASKA,CREIGHTON UNIV,MED CTR,NEBRASKA ONCOL GRP OMAHA NE 00000 DULUTH COMMUNITY CLIN ONCOL PROGRAM DULUTH MN 00000 IOWA ONCOL RES ASSOC,CCOP DES MOINES IA 00000 CEDAR RAPIDS ONCOL PROJECT,CCOP CEDAR RAPIDS IA 00000 MERITCARE HOSP,CCOP FARGO ND 00000
Titolo Testata:
International journal of radiation oncology, biology, physics
fascicolo: 2, volume: 35, anno: 1996,
pagine: 299 - 303
SICI:
0360-3016(1996)35:2<299:OICDPR>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
ULCERATIVE-COLITIS; AZODISAL SODIUM; TOLERANCE;
Keywords:
OLSALAZINE; PELVIC RADIATION THERAPY; ADVERSE EFFECTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
J.A. Martenson et al., "OLSALAZINE IS CONTRAINDICATED DURING PELVIC RADIATION-THERAPY - RESULTS OF A DOUBLE-BLIND, RANDOMIZED CLINICAL-TRIAL", International journal of radiation oncology, biology, physics, 35(2), 1996, pp. 299-303

Abstract

Purpose: A randomized clinical trial from Great Britain suggested a possible beneficial effect of acetylsalicylate in the prevention of radiation-induced bowel toxicity, Olsalazine is an orally administered drug designed to deliver 5-aminosalicylate to the large bowel with minimal systemic absorption, A randomized clinical trial was undertaken to assess the effectiveness of olsalazine in preventing acute diarrhea inpatients receiving pelvic radiation therapy. Methods and Materials: Patients receiving pelvic radiation therapy were randomized, in double-blind fashion, to olsalazine 250 mg, two capsules twice daily, or an identical appearing placebo, two capsules twice daily, Patients were then evaluated weekly during radiation therapy for the primary study endpoint, diarrhea, as well as rectal bleeding, abdominal cramping, and tenesmus. Results: The study was closed early, after entry of 58 evaluable patients, when a preliminary analysis showed excessive diarrhea inpatients randomized to olsalazine, The incidence and severity of diarrhea were worse in patients randomized to olsalazine (p = 0.0036), Sixty percent of the patients randomized to olsalazine experienced Grade 3 or 4 diarrhea compared to only 14% randomized to placebo, There was also a trend toward higher incidence and greater severity of abdominalcramping in patients who were randomized to olsalazine (p = 0.084). Conclusion: Administration of olsalazine during pelvic radiation therapy resulted in an increased incidence and severity of diarrhea, Olsalazine is contraindicated in patients receiving pelvic radiation therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 20:43:44